Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial (2016) Eigentler TK, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D, Hoelzle E, et al. Journal article Targeted next-generation sequencing identifies molecular subgroups in squamous cell carcinoma of the head and neck with distinct outcome after concurrent chemoradiation (2016) Tinhofer I, Stenzinger A, Eder T, Konschak R, Niehr F, Endris V, Distel L, et al. Journal article Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial (2016) Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH, Hartmann A, et al. Journal article A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival (2015) Ugurel S, Loquai C, Kaehler K, Hassel J, Berking C, Zimmer L, Haubitz I, et al. Journal article Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project+ (2015) Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, et al. Journal article Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients (2015) Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, Gleisner S, et al. Journal article Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy (2015) Lindner JL, Loibl S, Denkert C, Ataseven B, Fasching P, Pfitzner BM, Gerber B, et al. Journal article Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)+ (2014) Von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching P, Tesch H, et al. Journal article Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial (2014) Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, Marshall E, et al. Journal article Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine (2014) Grob JJ, Amonkar MM, Martin-Algarra S, Demidov LV, Goodman V, Grotzinger K, Haney P, et al. Journal article